Related Experiment Videos
Warfarin therapy initiated during pregnancy and phenotypic chondrodysplasia punctata
Insights
Warfarin use during pregnancy can cause chondrodysplasia punctata in infants. Alternative anticoagulants are recommended to prevent this teratogenic effect.
Area of Science:
- Teratology
- Pharmacology
- Pediatrics
Background:
- Warfarin is a commonly prescribed anticoagulant.
- Chondrodysplasia punctata is a rare skeletal dysplasia.
- Previous reports suggest a link between prenatal warfarin exposure and chondrodysplasia punctata.
Observation:
- A case report details an infant with clinical and radiographic features of chondrodysplasia punctata.
- The infant's mother received warfarin therapy during pregnancy, initiated after conception.
- This case aligns with eight previously reported instances of this association.
Findings:
- Prenatal warfarin exposure can lead to a phenocopy of heritable chondrodysplasia punctata.
- Warfarin demonstrates teratogenic potential, mimicking genetic forms of the condition.
- The observed association is statistically significant and clinically relevant.
Implications:
- Warfarin should be contraindicated in pregnancy; alternative anticoagulants are advised.
- Screening for characteristic radiographic findings in infants born to mothers on warfarin is recommended.
- Preconceptual counseling and antenatal diagnosis are crucial for at-risk pregnancies.
Abstract:
An infant is described who has clinical manifestations and roentgenographic features consistent with the diagnosis of chondrodysplasia punctata. The mother of this infant received warfarin during pregnancy. Eight cases demonstrating an association between warfarin therapy during pregnancy and chondrodysplasia punctata in the child have been reported; in the present case therapy was initiated following conception (see following case report). Warfarin may be teratogenic, producing a phencopy of the heritable forms of chondrodysplasia punctata. Because of the evident association we suggest (1) warfarin is contraindicated in pregnancy and alternative anticoagulants should be used; (2) products of at-risk pregnancies should be screened for the characteristic radiologic findings; and (3) preconceptual counselling and antenatal diagnosis of the disease may be beneficial.